Citadel Advisors
SBBP

Citadel Advisors’s Strongbridge Biopharma plc. SBBP Stock Holding History

Citadel Advisors’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20,300
Closed -$60K – 15221
2021
Q2 		$60K Sell
20,300
-8,200
-29% -$21.7K ﹤0.01% 13256
2021
Q1 		$79K Buy
28,500
+8,400
+42% +$25.3K ﹤0.01% 12645
2020
Q4 		$49K Buy
20,100
+2,800
+16% +$6.75K ﹤0.01% 10572
2020
Q3 		$36K Buy
17,300
+4,200
+32% +$14.2K ﹤0.01% 9714
2020
Q2 		$50K Buy
+13,100
New +$39.3K ﹤0.01% 9308

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Citadel Advisors's SBBP Position: Q3 2021 in Review

Citadel Advisors sold out of Strongbridge Biopharma plc. (SBBP) in Q3 2021, closing a stake of 19,499 shares — an estimated $58K sold.

Citadel Advisors first reported a position in SBBP in Q1 2018 and held it in 8 quarters. The position peaked at $235K in Q1 2020. 49 funds tracked by Wall St. Rank hold SBBP as of Q3 2021.

  • Citadel Advisors reported no remaining Strongbridge Biopharma plc. position as of Q3 2021 after selling out during the quarter.
  • Citadel Advisors sold 19,499 Strongbridge Biopharma plc. shares in Q3 2021, an estimated $58K.
  • Citadel Advisors first reported a position in Strongbridge Biopharma plc. in Q1 2018 and held it in 8 quarters.
  • Citadel Advisors's Strongbridge Biopharma plc. position peaked at $235K in Q1 2020.
  • 49 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q3 2021.

Based on Citadel Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.